NCT04089189View on ClinicalTrials.gov

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

December 17, 2024

Conditions
Ovarian Cancer
Interventions
DRUG

IMP4297

IMP4297 100mg PO QD

Trial Locations (1)

Unknown

Xiaohua.Wu, Shanghai

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY

NCT04089189 - Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer | Biotech Hunter | Biotech Hunter